StudyID,Drug_Name,Prot_No,NCT_No,EUCT_No,Other_No,Inv_Prod,Study_Phase,Start_Date,Termin_Date,Complet_Date,Data_Cutoff_Date,Name_PI,Sponsor,GCP_Compliance,Study_First_Posted_Date,Route_Admin,Treat_Duration,Add_On_Treat,Arm_Description,Adherence_Treat,MRCT,No_Center,No_Center_NA,No_Center_AP,No_Center_WEU,No_Center_EEU,No_Center_AF,Enroll_Duration_Plan,FU_Duration_Plan,Central_Lab,Run_in,DMC
NCT01673867,Nivolumab; Docetaxel,CA209-057,NCT01673867,2012-002472-14,,Nivolumab,Phase 3,"November 2, 2012",,"December 17, 2021",,,Bristol-Myers Squibb,,"August 28, 2012",iv,"until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends",,"Arm A: Nivolumab: Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.; Arm B: Docetaxel: Docetaxel 75 mg/m^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.",,Yes,117,33,9,35,16,0,,,Yes,,No
